Moderna’s Bid for BioNTech’s Idled Plants Puts a Hard Data Floor Under the mRNA Story

BioNTech slashes costs, closes three German factories and a Singapore site, cutting 1,860 jobs. Moderna eyes idle plants as the mRNA pioneer pivots to oncology with pivotal trial readouts ahead.

Thirteen billion doses. An 87% efficacy rate against infection. A 94% shield against fatal outcomes. Those are the freshly updated safety and effectiveness figures for BioNTech’s COVID-19 vaccine — numbers that, by any measure, validate the underlying mRNA platform. Yet for the Mainz-based company, the pandemic is ancient history. Revenue in the latest quarter slumped to €118 million, and the net loss widened to €532 million. The contrast between the technology’s proven power and the commercial vacuum it now faces sets the stage for a dramatic corporate overhaul.

The response has been sharp. BioNTech will shutter its production sites in Idar-Oberstein, Marburg and Tübingen by the end of next year, along with a facility in Singapore. The closures are the centerpiece of a cost-cutting drive designed to save €500 million annually by 2029 and will put roughly 1,860 jobs on the line. The move might seem puzzling given the company’s war chest of nearly €17 billion in cash and securities, but management sees no alternative as it tries to shed the label of a one-pandemic wonder and reposition itself as a mid-cap oncology player.

That restructuring has caught the eye of an unlikely suitor. Stéphane Bancel, CEO of U.S. rival Moderna, confirmed to Handelsblatt that his company is interested in acquiring the soon-to-be-idle German factories. Buying existing plants would be cheaper than building from scratch in Germany, Bancel said, and Moderna would also be willing to absorb some of the displaced BioNTech employees. Any deal, however, hinges on finding the right partnership with the German federal government — and the political climate is not uniformly hospitable. Germany is reining in health spending, and the pullback has already prompted Eli Lilly and Boehringer Ingelheim to reconsider planned factory investments, including a facility dedicated to GLP-1 drugs. Whether the government will extend a welcoming hand to Moderna remains an open question.

Against that backdrop, BioNTech has moved to soothe shareholder nerves with a $1 billion share buyback on Nasdaq, capped at 25 million shares and executed through an independent bank to avoid market distortion. The program has helped stabilize the stock since its June launch, but the real value for investors lies elsewhere.

All eyes are on the oncology pipeline, where seven critical readouts are on deck. Phase 3 data for gotistobart in non-small cell lung cancer and for the mRNA therapy BNT113 in head and neck tumors are among the most anticipated. In addition, five new registration studies have been opened for pumitamig, a candidate targeting breast and stomach cancers. That brings BioNTech’s total number of parallel registration trials to 13. The secondary article reminds readers that Pfizer is also collecting clinical data on the latest KP.2 vaccine variant for the 2024/2025 season, but analysts have made it clear: the next significant catalyst for the equity is tangible proof that the mRNA platform can deliver in oncology, not infectious disease.

The stock’s recent behavior reflects the wait-and-see mood. On Thursday it closed at €82.40, barely changed from the previous day’s €82.45. A session earlier it had touched €81.95, a 0.61% dip. Over 30 days the shares have gained about 7.5% and sit more than 20% above their year low of €68.35 from March. The all-time high of €105.80 set in January is still 22% out of reach. Technically, the price hovers just above the 50-day moving average (€80.07–€80.08) but remains below the 200-day line (€85.35). Annualized volatility runs near 29%.

Two uncertainties will define the months ahead: whether Berlin rolls out the welcome mat for Moderna’s factory bid, and whether the torrent of cancer data due in the second half delivers the validation that BioNTech’s shareholders desperately need.